Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women
Date
1997
Authors
Nestel, Paul J.
Yamashita, Takeshi
Sasahara, Takayuki
Pomeroy, Sylvia
Dart, Anthony
Komesaroff, Paul
Owen, Alice
Abbey, Mavis
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Arteriosclerosis, Thrombosis and Vascular Biology, 1997; 17:3392-3398
Statement of Responsibility
Paul J. Nestel, Takeshi Yamashita, Takayuki Sasahara, Sylvia Pomeroy, Anthony Dart, Paul Komesaroff, Alice Owen and Mavis Abbey
Conference Name
Abstract
The possibility that the heightened cardiovascular risk associated with the menopause, which is said to be ameliorated by soybeans, can be reduced with soy isoflavones was tested in 21 women. Although several were perimenopausal, all have been included. A placebo-controlled crossover trial tested the effects of 80-mg daily isoflavones (45 mg genistein) over 5- to 10-week periods. Systemic arterial compliance (arterial elasticity), which declined with age in this group, improved 26% (P<.001) compared with placebo. Arterial pressure and plasma lipids were unaffected. The vasodilatory capacity of the microcirculation was measured in nine women; high acetylcholine-mediated dilation in the forearm vasculature was similar with active and placebo treatments. LDL oxidizability measured in vitro was unchanged. Thus, one important measure of arterial health, systemic arterial compliance, was significantly improved in perimenopausal and menopausal women taking soy isoflavones to about the same extent as is achieved with conventional hormone replacement therapy
School/Discipline
Dissertation Note
Provenance
Description
© 1997 American Heart Association, Inc.